
The introduction of the tyrosine kinase inhibitor imatinib mesylate (Gleevec) has profoundly changed the treatment paradigm for patients with chronic myelogenous leukemia (CML).

Your AI-Trained Oncology Knowledge Connection!


Published: April 15th 2008 | Updated: